Phase II study of stereotactic body radiotherapy to primary tumor and metastatic locations in oligometastatic nonsmall-cell lung cancer patients

Annals of Oncology

Volumn 25, Issue 10, 2014, Pages 1954-1959

  Collen, C ^a   Christian, N ^a   Schallier, D ^a   Meysman, M ^a   Duchateau, M ^a   Storme, G ^a   De Ridder, M ^a  

^a UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

Author keywords

consolidation; oligometastatic NSCLC; stereotactic body radiotherapy; uncontrolled primary tumors

Indexed keywords

ADVERSE EFFECTS; AGED; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL; DISEASE FREE SURVIVAL; FEMALE; HUMAN; MALE; METASTASIS; MIDDLE AGED; PATHOLOGY; PHASE 2 CLINICAL TRIAL; PROCEDURES; PROGNOSIS; PROSPECTIVE STUDY; RADIOSURGERY; TREATMENT OUTCOME;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROGNOSIS; PROSPECTIVE STUDIES; RADIOSURGERY; TREATMENT OUTCOME;

EID: 84912075430     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu370     Document Type: Article

References (19)

1. Aupérin, A., Le Péchoux, C., Rolland, E., et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol 28 (2010), 2181–2190.
2. Non-Small Cell Lung Cancer collaborative Group, Chemotherapy and supportive care versus supportive care alone for advanced non-small cell lung cancer. Cochrane Database Syst Rev, 5, 2010, CD007309.
3. Schiller, J.H., Harrington, D., Belani, C.P., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346 (2002), 92–98.
4. Ashworth, A., Rodrigues, G., Boldt, G., et al. Is there an oligometastatic state in non-small cell lung cancer? A systematic review of the literature. Lung Cancer 82 (2013), 197–203.
5. Salah, S., Tanvetyanon, T., Abbasi, S., Metastatectomy for extra-cranial extra-adrenal non-small cell lung cancer solitary metastases: systematic review and analysis of reported cases. Lung Cancer 75 (2012), 9–14.
6. Yano, T., Haro, A., Yoshida, T., Prognostic impact of local treatment against postoperative oligometastases in NSCLC. J Surg Oncol 102 (2010), 852–855.
7. Alongi, F., Arcangeli, S., Filippi, A., et al. Review and uses of stereotactic body radiation therapy for oligometastases. Oncologist 17 (2012), 1100–1107.
8. Tree, A., Khoo, V., Eeles, R., et al. Stereotactic body radiotherapy for oligometastases. Lancet Oncol 14 (2013), 28–637.
9. De Ruysscher, D., Wanders, R., van Baardwijk, A., et al. Radical treatment of non-small-cell lung cancer patients with synchronous oligometastases: long-term results of a prospective phase II trial. J Thorac Oncol 7 (2012), 1547–1555.
10. Griffioen, G., Toguri, D., Dahele, M., et al. Radical treatment of synchronous oligometastatic non-small cell lung carcinoma (NSCLC): patient outcomes and prognostic factors. Lung Cancer 82 (2013), 95–102.
11. Rusch, V., Asamura, H., Watanabe, H., et al., on behalf of the members of the IASLC Staging Committee, The IASLC Lung Cancer Staging Project: a proposal for a new international lymph node map in the forthcoming seventh edition of the TNM classification for lung cancer. J Thorac Oncol 4 (2009), 568–577.
12. Engels, B., Everaert, H., Gevaert, T., et al. Phase II study of helical tomotherapy for oligometastatic colorectal cancer. Ann Oncol 22 (2011), 362–368.
13. Engels, B., Gevaert, T., Everaert, H., et al. Phase II study of helical tomotherapy in the multidisciplinary treatment of oligometastatic colorectal cancer. Radiat Oncol, 7, 2012, 34.
14. Wahl, R.L., Jacene, H., Kasamon, Y., Lodge, M.A., From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med 50 (2009), 122S–150S.
15. Milano, M.T., Katz, A.W., Zhang, H., et al. Oligometastases treated with stereotactic body radiotherapy: long-term follow-up of prospective study. Int J Radiat Oncol Biol Phys 83 (2012), 878–886.
16. Hasselle, M., Haraf, D., Rusthoven, K., et al. Hypofractionated image-guided radiation therapy for patients with limited volume metastatic non-small cell lung cancer. J Thorac Oncol 7 (2012), 379–381.
17. De Vin, T., Engels, B., Gevaert, T., et al. Stereotactic radiotherapy for oligometastatic cancer: a prognostic model for survival. Ann Oncol 25 (2014), 467–471.
18. Paz-Ares, L.G., de Marinis, F., Dediu, M., et al. PARAMOUNT: final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small cell lung cancer. J Clin Oncol 31 (2013), 2895–2902.
19. Palma, D.A., Haasbeek, C., Rodrigues, G., et al. Stereotactic ablative radiotherapy for comprehensive treatment of oligometastatic tumors (SABR-COMET): study protocol for a randomized phase II trial. BMC Cancer, 12, 2012, 305.